This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Casteels, K. M. Articles by Bouillon, R. Search for Related Content PubMed PubMed Citation Articles by Casteels, K. M. Articles by Bouillon, R.

Prevention of Type I Diabetes in Nonobese Diabetic Mice by Late Intervention with Nonhypercalcemic Analogs of 1,25-Dihydroxyvitamin D₃ in Combination with a Short Induction Course of Cyclosporin A¹

Laboratory for Experimental Medicine and Endocrinology (K.M.C., C.M., D.V., J.M.L., R.B.) and the Laboratory for Experimental Transplantation (M.W., L.O.), Gasthuisberg; Catholic University of Leuven, 3000 Leuven, Belgium

Address all correspondence and requests for reprints to: Dr. Roger Bouillon, Legendo, U.Z. Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. E-mail: Roger.Bouillon{at}Med.Kuleuven.ac.be

In nonobese diabetic (NOD) mice, type I diabetes can be prevented without generalized immunosuppression by nonhypercalcemic analogs of vitamin D₃ when treatment is started early, i.e. before the autoimmune attack, reflected by insulitis, occurs. The aim of this study was to investigate whether these substances can arrest progression to clinically overt diabetes when administered in a more advanced disease stage, namely when the autoimmune attack is ongoing, reflecting the situation in prediabetic subjects in whom immune intervention is being considered. We, therefore, evaluated the protective potential of MC1288 (20-epi-1,25-dihydroxyvitamin D₃) a nonhypercalcemic analog of 1,25-dihydroxyvitamin D₃, both alone and in combination with a short induction course of cyclosporin A, in NOD mice that already have insulitis, as demonstrated in pancreatic biopsies performed 15 days before the start of therapy. Subsequently, mice were randomized into a control group, receiving the treatment vehicle (n = 26), and three treatment groups, receiving, respectively, 7.5 mg/kg·day cyclosporin A (CyA) from days 85–105 (n = 19), 0.1 µg/kg·2 days MC1288 from days 85–200 (n = 20), or the combination of these two regimens (n = 20). At the time of the pancreatic biopsy (day 70), insulitis was evenly distributed in all groups, and 27.7% of the islets scored showed signs of destructive insulitis. Diabetes outcome by 200 days was 74% (14 of 19) in the CyA-treated group, comparable to the diabetes incidence in control mice (65%; 17 of 26; P = NS). Treatment with MC1288 alone could not reduce disease incidence (70%; 14 of 20), but the combination therapy reduced diabetes incidence to 35% (7 of 20; P < 0.05 vs. untreated; P < 0.01 vs. CyA group; P < 0.025 vs. MC1288). All treatments were well tolerated, without major side-effects on calcium or bone metabolism and without signs of generalized immunosuppression. Cotransfer experiments could not reveal the induction of suppressor cells. Reverse transcription-PCR on pancreatic tissue revealed significantly lower levels of interferon- and higher levels of interleukin-4 in the combination group. In conclusion, nonhypercalcemic analogs of 1,25-dihydroxyvitamin D₃ administered to NOD mice when the autoimmune disease is already active can prevent clinical diabetes when this therapy is combined with a short induction course of an immunosuppressant such as CyA.

This article has been cited by other articles:

				G. E. Mullin and A. Dobs Vitamin D and Its Role in Cancer and Immunity: A Prescription for Sunlight Nutr Clin Pract, June 1, 2007; 22(3): 305 - 322. [Abstract] [Full Text] [PDF]

				C. L.-T. Chang, S.-L. Chang, Y.-M. Lee, Y.-M. Chiang, D.-Y. Chuang, H.-K. Kuo, and W.-C. Yang Cytopiloyne, a Polyacetylenic Glucoside, Prevents Type 1 Diabetes in Nonobese Diabetic Mice J. Immunol., June 1, 2007; 178(11): 6984 - 6993. [Abstract] [Full Text] [PDF]

				C. A. Gysemans, A. K. Cardozo, H. Callewaert, A. Giulietti, L. Hulshagen, R. Bouillon, D. L. Eizirik, and C. Mathieu 1,25-Dihydroxyvitamin D3 Modulates Expression of Chemokines and Cytokines in Pancreatic Islets: Implications for Prevention of Diabetes in Nonobese Diabetic Mice Endocrinology, April 1, 2005; 146(4): 1956 - 1964. [Abstract] [Full Text] [PDF]

				A. G.S. van Halteren, E. van Etten, E. C. de Jong, R. Bouillon, B. O. Roep, and C. Mathieu Redirection of Human Autoreactive T-Cells Upon Interaction With Dendritic Cells Modulated by TX527, an Analog of 1,25 Dihydroxyvitamin D3 Diabetes, July 1, 2002; 51(7): 2119 - 2125. [Abstract] [Full Text] [PDF]

				S. Gregori, N. Giarratana, S. Smiroldo, M. Uskokovic, and L. Adorini A 1{alpha},25-Dihydroxyvitamin D3 Analog Enhances Regulatory T-Cells and Arrests Autoimmune Diabetes in NOD Mice Diabetes, May 1, 2002; 51(5): 1367 - 1374. [Abstract] [Full Text] [PDF]

				J. Ermann, V. Szanya, G. S. Ford, V. Paragas, C. G. Fathman, and K. Lejon CD4+CD25+ T Cells Facilitate the Induction of T Cell Anergy J. Immunol., October 15, 2001; 167(8): 4271 - 4275. [Abstract] [Full Text] [PDF]

				N. Emoto, Y. Nurhantari, H. Alimsardjono, J. Xie, T. Yamada, M. Yanagisawa, and M. Matsuo Constitutive Lysosomal Targeting and Degradation of Bovine Endothelin-converting Enzyme-1a Mediated by Novel Signals in Its Alternatively Spliced Cytoplasmic Tail J. Biol. Chem., January 15, 1999; 274(3): 1509 - 1518. [Abstract] [Full Text] [PDF]